PDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals
暂无分享,去创建一个
A. Olivi | A. Cameron | A. Felsani | A. Mangiola | M. Puglisi | G. Sica | P. Casalbore | C. Cenciarelli | H. Marei
[1] D. Figarella-Branger,et al. A Positive Feed-forward Loop Associating EGR1 and PDGFA Promotes Proliferation and Self-renewal in Glioblastoma Stem Cells* , 2016, The Journal of Biological Chemistry.
[2] R. Bernards,et al. Targeting the RB-E2F pathway in breast cancer , 2016, Oncogene.
[3] K. McDonald,et al. CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future? , 2015, Front. Oncol..
[4] P. Canoll,et al. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo , 2015, Oncotarget.
[5] Lihua Huang,et al. Mechanisms of resistance to EGFR tyrosine kinase inhibitors , 2015, Acta pharmaceutica Sinica. B.
[6] K. Aldape,et al. Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice , 2015, Clinical Cancer Research.
[7] A. Giordano,et al. RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy , 2015, Oncotarget.
[8] L. Qin,et al. WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis , 2015, Oncotarget.
[9] PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment , 2014, Molecular Cancer.
[10] C. Heldin,et al. Targeting the PDGF signaling pathway in tumor treatment , 2013, Cell Communication and Signaling.
[11] B. Zhou,et al. The Role of Snail in EMT and Tumorigenesis. , 2013, Current cancer drug targets.
[12] F. Spinella,et al. Endothelin 1 in cancer: biological implications and therapeutic opportunities , 2013, Nature Reviews Cancer.
[13] Elgene Lim,et al. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. , 2013, Cancer cell.
[14] Milena B. Furtado,et al. Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide , 2013, Cell Death and Disease.
[15] Y. Nakanishi,et al. Serum protein kinase Cα as a diagnostic biomarker of cancers. , 2013, Cancer biomarkers : section A of Disease markers.
[16] J. Balça-Silva,et al. PKC signaling in glioblastoma , 2013, Cancer biology & therapy.
[17] Isabelle Salmon,et al. A Simplified Approach for the Molecular Classification of Glioblastomas , 2012, PloS one.
[18] G. Konopka,et al. STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation , 2012, The Journal of Neuroscience.
[19] Qiulian Wu,et al. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. , 2012, Genes & development.
[20] A. Heerschap,et al. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models , 2011, The Journal of pathology.
[21] Jiankai Xu,et al. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. , 2011, International journal of oncology.
[22] A. Satelli,et al. Vimentin as a potential molecular target in cancer therapy Or Vimentin , an overview and its potential as a molecular target for cancer therapy , 2011 .
[23] S. Nelson,et al. Autocrine endothelin-3 / endothelin receptor B signaling maintains cellular and molecular properties of tumorigenic glioblastoma stem cells , 2011 .
[24] Chih-Chiang Chien,et al. 12‐O‐tetradecanoylphorbol‐13‐acetate‐induced invasion/migration of glioblastoma cells through activating PKCα/ERK/NF‐κB‐dependent MMP‐9 expression , 2010, Journal of cellular physiology.
[25] A. Falini,et al. Cancer esearch cular and Cellular Pathobiology ermal Growth Factor Receptor Expression Identifies ctionally and Molecularly Distinct Tumor-Initiating Cells uman Glioblastoma Multiforme and Is Required R Gliomagenesis , 2010 .
[26] Richard Beyer,et al. TWIST1 promotes invasion through mesenchymal change in human glioblastoma , 2010, Molecular Cancer.
[27] M. Prados,et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.
[28] K. Nakashiro,et al. Conditional deletion of Stat3 promotes neurogenesis and inhibits astrogliogenesis in neural stem cells. , 2010, Biochemical and biophysical research communications.
[29] W. Mason,et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Brennan,et al. Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.
[31] B. Cochran,et al. STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells , 2009, Stem cells.
[32] A. Bonni,et al. STAT3 regulation of glioblastoma pathogenesis. , 2009, Current molecular medicine.
[33] G. Maira,et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution , 2009, Oncogene.
[34] Rakesh K. Jain,et al. PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment , 2009, PloS one.
[35] Leigh Zawel,et al. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. , 2008, The Journal of clinical investigation.
[36] J. Rich,et al. Antiangiogenic therapy in malignant glioma: promise and challenge. , 2007, Current pharmaceutical design.
[37] R. Herbst,et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] E. Holland,et al. Platelet-derived growth factor (PDGF) and glial tumorigenesis. , 2006, Cancer letters.
[39] G. Pilkington,et al. Cancer stem cells in the mammalian central nervous system , 2005, Cell proliferation.
[40] M. Israel,et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. , 2002, Cancer research.
[41] Olav Haraldseth,et al. NG2 proteoglycan promotes angiogenesis‐dependent tumor growth in the central nervous system by sequestering angiostatin , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[42] Yuji Saito,et al. Receptor Heterodimerization: Essential Mechanism for Platelet-Derived Growth Factor-Induced Epidermal Growth Factor Receptor Transactivation , 2001, Molecular and Cellular Biology.
[43] Yasuhiro Yonekawa,et al. Promoter Hypermethylation of the RB1 Gene in Glioblastomas , 2001, Laboratory Investigation.
[44] K. Ichimura,et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. , 2000, Cancer research.
[45] J. Harbour,et al. Cdk Phosphorylation Triggers Sequential Intramolecular Interactions that Progressively Block Rb Functions as Cells Move through G1 , 1999, Cell.
[46] M. Greenberg,et al. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. , 1997, Science.
[47] V P Collins,et al. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. , 1996, Oncogene.
[48] C. Heldin,et al. Interaction between NG2 proteoglycan and PDGF α‐receptor on O2A progenitor cells is required for optimal response to PDGF , 1996, Journal of neuroscience research.
[49] M. Pagano,et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. , 1993, Genes & development.
[50] E. Oldfield,et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.
[51] S. Finkelstein,et al. Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression. , 1992, Cancer research.
[52] A. Fields,et al. Protein kinase C isoforms in human glioblastoma cells , 1992, Glia.
[53] W. Birchmeier,et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells , 1991, The Journal of cell biology.